Home Healthcare Pharmaceuticals Pemphigus Vulgaris Market

Pemphigus Vulgaris Market Size, Share & Trends Analysis Report By Treatment (Corticosteroids, Immunosuppressants, Biological Therapies, Intravenous Immunoglobulin (IVIG) Therapy, Others), By Route of Administration (Intravenous, Subcutaneous, Oral), By End-User (Hospitals and Clinics, Specialty Dermatology Clinics, Research and Academic Laboratories, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Mitiksha Koul | Format: | Report Code: SR3943DR | Pages: 160
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Pemphigus Vulgaris Market, By Treatment 2022-2034 (USD MILLION/ Units)
    1. Corticosteroids
    2. Immunosuppressants
    3. Biological Therapies
    4. Intravenous Immunoglobulin (IVIG) Therapy
    5. Others
  2. Pemphigus Vulgaris Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Intravenous
    2. Subcutaneous
    3. Oral
  3. Pemphigus Vulgaris Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Hospitals and Clinics
    2. Specialty Dermatology Clinics
    3. Research and Academic Laboratories
    4. Others
  4. Regional Pemphigus Vulgaris Market
    1. North America
      1. North America Pemphigus Vulgaris Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
      2. North America Pemphigus Vulgaris Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous
        2. Subcutaneous
        3. Oral
      3. North America Pemphigus Vulgaris Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Clinics
        2. Specialty Dermatology Clinics
        3. Research and Academic Laboratories
        4. Others
      4. U.S.
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      5. Canada
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
    2. Europe
      1. Europe Pemphigus Vulgaris Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
      2. Europe Pemphigus Vulgaris Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous
        2. Subcutaneous
        3. Oral
      3. Europe Pemphigus Vulgaris Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Clinics
        2. Specialty Dermatology Clinics
        3. Research and Academic Laboratories
        4. Others
      4. U.K.
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      5. Germany
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      6. France
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      7. Spain
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      8. Italy
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      9. Russia
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      10. Nordic
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      11. Benelux
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      12. Rest of Europe
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
    3. APAC
      1. APAC Pemphigus Vulgaris Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
      2. APAC Pemphigus Vulgaris Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous
        2. Subcutaneous
        3. Oral
      3. APAC Pemphigus Vulgaris Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Clinics
        2. Specialty Dermatology Clinics
        3. Research and Academic Laboratories
        4. Others
      4. China
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      5. Korea
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      6. Japan
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      7. India
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      8. Australia
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      9. Taiwan
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      10. South East Asia
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      11. Rest of Asia-Pacific
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
    4. Middle East and Africa
      1. Middle East and Africa Pemphigus Vulgaris Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
      2. Middle East and Africa Pemphigus Vulgaris Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous
        2. Subcutaneous
        3. Oral
      3. Middle East and Africa Pemphigus Vulgaris Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Clinics
        2. Specialty Dermatology Clinics
        3. Research and Academic Laboratories
        4. Others
      4. UAE
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      5. Turkey
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      6. Saudi Arabia
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      7. South Africa
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      8. Egypt
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      9. Nigeria
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      10. Rest of MEA
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
    5. LATAM
      1. LATAM Pemphigus Vulgaris Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
      2. LATAM Pemphigus Vulgaris Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous
        2. Subcutaneous
        3. Oral
      3. LATAM Pemphigus Vulgaris Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Clinics
        2. Specialty Dermatology Clinics
        3. Research and Academic Laboratories
        4. Others
      4. Brazil
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      5. Mexico
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      6. Argentina
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      7. Chile
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      8. Colombia
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
      9. Rest of LATAM
        1. Corticosteroids
        2. Immunosuppressants
        3. Biological Therapies
        4. Intravenous Immunoglobulin (IVIG) Therapy
        5. Others
        6. Intravenous
        7. Subcutaneous
        8. Oral
        9. Hospitals and Clinics
        10. Specialty Dermatology Clinics
        11. Research and Academic Laboratories
        12. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.